- $14.48m
- $19.60m
- $52.68m
Brief: Iridex Announces First Patient Enrollment In Micropulse® Tlt Clinical Study Conducted In Collaboration With Imperial College Healthcare Nhs Trust
Brief: Iridex- Medicare Administrative Contractors Retired Local Coverage Determinations That Restricted Cyclophotocoagulation
Brief: Iridex Q3 revenue USD 12.9 million
Brief: Iridex Announces Strategic Review To Unlock Shareholder Value
Iridex Corp Reports Results For The Quarter Ended In June: Earnings Summary
Iridex Corp Expected To Post A Loss Of 11 Cents A Share: Earnings Preview
Iridex Corp Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Iridex Reports First Quarter 2023 Financial Results
Iridex Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Iridex Corp Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Iridex Reports Fourth Quarter And Full Year 2022 Financial Results
Iridex Corp Expected To Post A Loss Of 11 Cents A Share: Earnings Preview
Brief: Iridex Announces Preliminary Results For Q4 And Full Year
Iridex Corp Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Iridex Announces Third Quarter 2022 Financial Results
Iridex Corp Expected To Post A Loss Of 14 Cents A Share: Earnings Preview
Brief: Glenn Cuthbert Roland Reports 5.52% Stake In Iridex Corp
U.S. STOCKS ON THE MOVE-PagSeguro Digital, Finch Therapeutics, Mastercard
Iridex drops as Stifel downgrades on low demand for glaucoma product